Latest Stories for GlycoMimetics, Inc.dlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-04-13:/organization/651082015-04-13T06:49:11-07:00<![CDATA[GlycoMimetics Provides Update on Pfizer’s Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015]]>tag:news.dlvr.it,2015-04-07:3731852015-04-07T04:00:52-07:00
– GlycoMimetics to receive $20 million milestone payment upon dosing
of first patient in trial –
]]><![CDATA[GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015]]>tag:news.dlvr.it,2015-03-19:3695192015-03-19T06:30:16-07:00]]><![CDATA[GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results]]>tag:news.dlvr.it,2015-03-16:3638742015-03-16T13:30:34-07:00
Year-End Cash and Cash Equivalents of $55.2 million
]]><![CDATA[GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease]]>tag:news.dlvr.it,2015-03-03:3473362015-03-03T06:06:10-08:00
- Data underscores potential to provide meaningful clinical
benefits and pharmacoeconomic impacts for patients in vaso-occlusive
crisis -
]]><![CDATA[GlycoMimetics to Present at Two Investor Conferences in March]]>tag:news.dlvr.it,2015-02-26:3515232015-02-26T06:04:47-08:00]]><![CDATA[GlycoMimetics to Present at 17th Annual BIO CEO & Investor Conference]]>tag:news.dlvr.it,2015-02-03:3410942015-02-03T06:05:48-08:00]]><![CDATA[GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting]]>tag:news.dlvr.it,2014-12-09:3306182014-12-09T06:09:01-08:00
Preclinical Data Shared Through Four Oral Presentations and One
Poster Focus on the Potential Role of GMI-1271 in Treating Blood
Cancers and Coagulation Disorders
Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via
Poster Session at ASH Meeting
]]><![CDATA[University of Michigan to Study GlycoMimetics’ GMI-1271 as Potential Treatment for Serious Blood-Clotting Disorder]]>tag:news.dlvr.it,2014-12-04:3165292014-12-04T06:04:07-08:00
- National Heart Lung and Blood Institute grant is funding
University of Michigan Phase 1 trial
]]><![CDATA[GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy Volunteers]]>tag:news.dlvr.it,2014-11-17:3187262014-11-17T13:00:13-08:00
- E-selectin antagonist GMI-1271 to advance to chemo-combination
study in AML -
]]><![CDATA[GlycoMimetics to Present at Stifel Healthcare Conference 2014]]>tag:news.dlvr.it,2014-11-12:3299782014-11-12T06:06:37-08:00]]><![CDATA[GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting]]>tag:news.dlvr.it,2014-11-06:3316042014-11-06T06:33:13-08:00
Preclinical data on GMI-1271 in four oral presentations and one
poster focus on blood cancers and coagulation disorders
New data for rivipansel, sickle cell investigational drug
candidate, show effects on biomarkers
]]><![CDATA[GlycoMimetics Reports Third Quarter 2014 Results]]>tag:news.dlvr.it,2014-10-31:3161892014-10-31T06:15:07-07:00]]><![CDATA[GlycoMimetics to Present at 34th Annual Canaccord Genuity Global Growth Conference]]>tag:news.dlvr.it,2014-08-08:2899912014-08-08T07:39:10-07:00]]><![CDATA[GlycoMimetics Reports Second Quarter 2014 Results]]>tag:news.dlvr.it,2014-07-31:2873332014-07-31T13:00:38-07:00]]><![CDATA[GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors]]>tag:news.dlvr.it,2014-07-10:2805782014-07-10T06:08:46-07:00
- Dr. Goldberg Brings Perspective as Medical Oncologist and
Hematologist and Extensive Biopharmaceutical Regulatory Experience to
GlycoMimetics Board -
]]>
– GlycoMimetics to receive $20 million milestone payment upon dosing
of first patient in trial –
]]>
]]>
Year-End Cash and Cash Equivalents of $55.2 million
]]>
- Data underscores potential to provide meaningful clinical
benefits and pharmacoeconomic impacts for patients in vaso-occlusive
crisis -
]]>
]]>
]]>
Preclinical Data Shared Through Four Oral Presentations and One
Poster Focus on the Potential Role of GMI-1271 in Treating Blood
Cancers and Coagulation Disorders
Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via
Poster Session at ASH Meeting
]]>
- National Heart Lung and Blood Institute grant is funding
University of Michigan Phase 1 trial
]]>
- E-selectin antagonist GMI-1271 to advance to chemo-combination
study in AML -
]]>
]]>
Preclinical data on GMI-1271 in four oral presentations and one
poster focus on blood cancers and coagulation disorders
New data for rivipansel, sickle cell investigational drug
candidate, show effects on biomarkers
]]>
]]>
]]>
]]>
- Dr. Goldberg Brings Perspective as Medical Oncologist and
Hematologist and Extensive Biopharmaceutical Regulatory Experience to
GlycoMimetics Board -
]]>